Europe Pancreatic Cancer Diagnostics Market, By Test Type (Imaging Test, Biopsy, Blood Test, Genomic Test, and Others), Cancer Stage (Stage 0, Stage I, Stage II, Stage III and Stage IV), Tumor Type (Exocrine Tumors and Neuroendocrine Tumors), Product (Instrument-Based Products, Platform-Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluoroimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Industry Trends and Forecast to 2030.
Europe Pancreatic Cancer Diagnostics Market Analysis and Insights
The growing prevalence of pancreatic cancer as well as increasing need for diagnostic products for these conditions have enhanced the market demand. The advancement in technology for easy supply of products and fast manufacturing facilities are also attributing in the growth of the market. The major market players are highly focusing on product launches and product approvals during this crucial period. In addition, the government and regulatory bodies are supporting market players by product approval due to surging emergence.
The Europe pancreatic cancer diagnostics market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in R&D activity for launching novel services in the market. The increasing research in the field of leukemia diagnosis and development is expected to further boost the market growth. However, difficulties in leukemia screening techniques is expected to hamper the growth of the Europe pancreatic cancer diagnostics market in the forecast period. Increasing healthcare expenditure on cancer diagnosis and treatment is expected to give opportunities to the market to enhance the treatment. The improvement in awareness about regular healthcare checkups, upcoming diagnostic centers and advancements in diagnostic methods for pancreatic cancer and technological developments is expected to boost the market’s growth. However, the high cost of testing and strict regulations and standards for the approval and commercialization of cancer diagnostic products and instruments is expected to challenge market growth.
The growing geriatric population, strategic initiatives by market players and government, and surge in healthcare expenditure give the market opportunities to enhance the treatment. However, the lack of skilled professionals and stringent regulatory frameworks are key challenges for the market growth. However, high cost of devices and treatments is expected to restrain the growth of the Europe pancreatic cancer diagnostics market.
The Europe pancreatic cancer diagnostics market is supportive and aims to reduce the disease thereby improving the recovery and performance of individuals. Data Bridge Market Research analyzes that Europe pancreatic cancer diagnostics market will grow at a CAGR of 7.6% during the forecast period of 2023 to 2030.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2020-2016)
|
|
Quantitative Units
|
Revenue in USD Million, Pricing in USD
|
|
Segments Covered
|
By Test Type (Imaging Test, Biopsy, Blood Test, Genomic Test, and Others), Cancer Stage (Stage 0, Stage I, Stage II, Stage III and Stage IV), Tumor Type (Exocrine Tumors and Neuroendocrine Tumors), Product (Instrument-Based Products, Platform-Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluoroimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others).
|
|
Countries Covered
|
Germany, United Kingdom, France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Turkey, Poland, Sweden, Norway, Denmark, Finland, Rest Of Europe.
|
|
Market Players Covered
|
Siemens Healthcare Private Limited, Koninklijke Philips N.V., FUJIFILM Corporation, Grail, Laboratory Corporation of America Holdings, DiaSource, Abbott, Agilent Technologies, Inc., Lee Biosolutions, Inc, MP BIOMEDICALS, Setia Scientific Solution, Boditech Med Inc., AccuBioTech Co., Ltd., Thermo Fisher Scientific, Creative Biolabs, Myriad Genetics, Inc., BD, CANON MEDICAL SYSTEMS CORPORATION, QIAGEN, Meridian Life Science, Inc., CTK Biotech, Inc., among others
|
Market Definition
Pancreatic cancer is fatal, and the diagnosis process of pancreatic cancer also has safety issues; it is not cost-effective. One of the most costly medical disorders to treat Europe is cancer. Cancer patients may be hospitalized and receive a variety of therapies for tumor, such as surgery, radiation treatment, and systemic therapy. Health insurance premiums for cancer patients are now more expensive than in the past. In addition, their copayment, deductible, and coinsurance costs are rising. Diagnosis of pancreatic cancer includes ultrasound, biopsy procedures and blood tests. Pancreatic cancer is one of the leading causes of death worldwide, and the prevalence of this disease has increased at an alarming rate.
Europe Pancreatic Cancer Diagnostics Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of these are discussed in detail below:
Drivers
- Grow in prevalence of pancreatic cancer
All ages can be affected by this type of cancer. Pancreatic cancer can be difficult to diagnose because, despite its wide range of signs and symptoms, they are non-specific and can be linked to other, more widespread medical conditions. Pancreatic cancer is the eighth most common cancer in women and the tenth most common cancer in men. Incidence rates of pancreatic cancer have gone up by around 1% each year. It occurs less frequently. It is slightly more common among women than men, however the average lifetime risk of getting pancreatic cancer in both sexes is about ½ of 1% on average. These conditions include: abdominal pain, loss of appetite or unintended weight loss, yellowing of skin and the whites of eyes (jaundice), light-colored stools, dark-colored urine and itchy skin.It is the 8th most common type of cancer diagnosed in adults and children, but most cases occur in adults. Although it can be diagnosed at any age, it is uncommon before age 45. The average age of diagnosis is age 68.
Due to various risk factors, pancreatic cancer incidence has been rising Europe, becoming a significant socio-economic issue. This is expected to act as a driver in the Europe pancreatic cancer diagnostics market.
- Novel technological advancements in pancreatic diagnostics
Pancreatic cancer is seldom detected at its early stages when it's most curable. This is because it often doesn't cause symptoms until after it has spread to other organs. Specialists must manually diagnose cancer and non-cancer cells by examining cell images under a microscope and providing labels through annotation. However, this hand microscopic examination is time-consuming and could give an incorrect diagnosis. The risk of prescribing the incorrect drugs was then reduced using computerized software. The creation of an automatic and reliable classification system became vital to stop the pancreatic disease's devastating effects. Multiple segmentation techniques constituted the foundation of the existing pancreatic cancer classification algorithms.
Opportunity
- Rise in healthcare expenditure for cancer diagnosis and treatment
Across the globe, research and development activities are escalating owing to the public health expenditure with economic performances. Whereas the healthcare industry ranks second among all industries when it comes to the amount spent on healthcare. Rising healthcare expenditure can result in better provision of research and development opportunities. It is anticipated to increase the demand for pancreatic cancer diagnostics. Increasing the healthcare expenditure for pancreatic cancer treatment also helps the patient take hassle-free advanced diagnostics and treatment for fast recovery. The spending on healthcare is made up of the combination of out-of-pocket payments (people paying for their care), government expenditure, and sources. It also includes health insurance and activities by non-governmental organizations. This increasing healthcare expenditure for cancer treatment is an opportunity for the market's demand.
Restraint/Challenge
- Late diagnosis and poor prognosis of pancreatic cancer
Late diagnosis of disease is due to the increasing pancreatic cancer tumors which do not respond as well to commonly used cancer therapies as other, less lethal types of cancer. But there are treatment options, including surgery, chemotherapy and radiation. There are different types of pancreatic cancer. Most pancreatic cancers are the exocrine type. This means that they start in cells that produce pancreatic digestive juices. About 30 percent of patients are smokers, and 5 percent have a history of pancreatitis, an inflammation of the pancreas, which can be caused by stones or heavy alcohol intake.
Post COVID-19 Impact on Europe Pancreatic Cancer Diagnostics Market
COVID-19 has negatively affected the growth of the market as patients suffering for pancreatic cancer postponed their surgery due to rapid surge in covid-19 cases across geographies. Additionally, people having pancreatic cancer were at risk of becoming severely ill. The fear of corona virus infection affected the growth of the pancreatic cancer diagnostic market amid pandemic.
Recent Developments
- In December 2022, FUJIFILM Holdings America Corporation announced the company has purchase agreement asset with Inspirata, Inc. to acquire digital pathology business to expand robust enterprise imaging offering. This results in enabling the integration of pathology images and data into a healthcare organization’s electronic health record system to streamline care delivery for oncology patients.
- In August 2020, Siemens Healthcare GmbH announced that it has entered in to an agreement with Varian Medical Systems, Inc. With this acquisition, Siemens Healthcare has helped in developing advanced solutions to treat against cancer and strengthen their position in healthcare industry.
Europe Pancreatic Cancer Diagnostics Market Scope
Europe pancreatic cancer diagnostics market is categorized into eight notable segments based on test type, cancer stages, tumor type, product, application, technology, end user and distribution channel.The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Test Type
- Imaging Test
- Biopsy
- Blood Test
- Genomic Test
- Others
On the basis of test type, the Europe pancreatic cancer diagnostics market is segmented into imaging test, biopsy, blood test, genomic test, and others.
Cancer Stage
- Stage 0
- Stage I
- Stage II
- Stage III
- Stage IV
On the basis of cancer stage, the Europe pancreatic cancer diagnostics market is segmented into stage 0, stage I, stage II, stage III and stage IV.
Tumor Type
- Exocrine Tumors
- Neuroendocrine Tumors
On the basis of tumor type, the Europe pancreatic cancer diagnostics market is segmented into exocrine tumors and neuroendocrine tumors.
Product
- Instrument-Based Products
- Platform-Based Products
- Kits and Reagents
- Other Consumables
On the basis of product, the Europe pancreatic cancer diagnostics market is segmented into instrument-based products, platform-based products, kits and reagents, and other consumables.
Application
- Screening
- Diagnostic And Predictive
- Prognostic
- Research
On the basis of application, the Europe pancreatic cancer diagnostics market is segmented into screening, diagnostic and predictive, prognostic, and research.
Technology
- Fluorescent In Situ Hybridization
- Next Generation Sequencing
- Fluoroimmunoassay
- Comparative Genomic Hybridization
- Immunohistochemical
- Others
On the basis of technology, the Europe pancreatic cancer diagnostics market is segmented into fluorescent in situ hybridization, next generation sequencing, fluoroimmunoassay, comparative genomic hybridization, immunohistochemical, and others.
End User
- Hospitals
- Diagnostic Centers
- Cancer Research Centers
- Academic Institutes
- Ambulatory Surgical Centers
- Others
On the basis of end user, the Europe pancreatic cancer diagnostics market is segmented into hospitals, diagnostic centers, cancer research centers, academic institutes, ambulatory surgical centers, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel, the Europe pancreatic cancer diagnostics market is segmented into direct tender, retail sales and others.
Europe Pancreatic Cancer Diagnostics Market Country Analysis/Insights
Europe pancreatic cancer diagnostics market is analyzed, and market size insights and trends are provided by the country, test type, cancer stages, tumor type, product, application, technology, end user and distribution channel as referenced above.
In 2023, Germany pancreatic cancer diagnostics market is expected to grow due to rise in prevalence and incidence of pancreatic cancer and increase in awareness about the pancreatic cancer diagnostics. These are the key contributing factors which is expected to boost the growth of the market in the country.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Pancreatic Cancer Diagnostics Market Share Analysis
Europe pancreatic cancer diagnostics market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the company’s focus on the Europe pancreatic cancer diagnostics market.
Some of the major players operating in the market are Siemens Healthcare Private Limited, Koninklijke Philips N.V., FUJIFILM Corporation, Grail, Laboratory Corporation of America Holdings, DiaSource, Abbott, Agilent Technologies, Inc., Lee Biosolutions, Inc, MP BIOMEDICALS, Setia Scientific Solution, Boditech Med Inc., AccuBioTech Co., Ltd., Thermo Fisher Scientific, Creative Biolabs, Myriad Genetics, Inc., BD, CANON MEDICAL SYSTEMS CORPORATION, QIAGEN, Meridian Life Science, Inc., CTK Biotech, Inc., among others.
SKU-